Clinical Uses of Intravenous Magnesium Sulfate
Intravenous magnesium sulfate has four primary evidence-based indications: prevention and treatment of eclampsia in preeclampsia, treatment of torsades de pointes and drug-induced QT prolongation, management of digoxin toxicity with ventricular arrhythmias, and correction of hypomagnesemia.
Obstetric Indications
Preeclampsia and Eclampsia Prevention
MgSO4 is the definitive therapy for preventing eclamptic seizures, reducing seizure risk by approximately 50%—you need to treat 100 women to prevent one seizure 1. The ISSHP guidelines strongly recommend that all preeclamptic women in low- and middle-income countries receive MgSO4, while in high-resource settings with specialized centers, selective use based on severity markers is reasonable 1.
Dosing regimen 2:
- Loading dose: 4-5 g IV over 3-4 minutes (diluted to 10-20% concentration), simultaneously with 10 g IM (5 g in each buttock)
- Maintenance: 4-5 g IM every 4 hours into alternate buttocks, OR 1-2 g/hour continuous IV infusion
- Target serum level: 6 mg/100 mL (optimal for seizure control)
- Duration: Continue for 24 hours postpartum, though some evidence suggests stopping after 8 g total if given before delivery may be sufficient 1
- Maximum daily dose: 30-40 g per 24 hours 2
Critical safety monitoring 2:
- Patellar reflexes must remain present
- Respiratory rate >12/minute
- Urine output >25-30 mL/hour
- In renal insufficiency: maximum 20 g/48 hours with frequent serum levels
Important caveat: Continuous maternal administration beyond 5-7 days can cause fetal abnormalities 2.
Cardiac Arrhythmia Indications
Torsades de Pointes and Drug-Induced QT Prolongation
For recurrent torsades de pointes with acquired QT prolongation, IV magnesium sulfate is the Class I recommended treatment, even when serum magnesium is normal 3. This represents a Class I, Level C-LD recommendation from the 2017 AHA/ACC/HRS guidelines.
Dosing for torsades 3:
- Initial bolus: 1-2 g IV push
- Repeated doses: Titrate to suppress ectopy and nonsustained VT episodes
- Magnesium suppresses torsades without necessarily shortening QT interval
- Combine with potassium repletion to ≥4.0-4.5 mmol/L (target 4.5-5.0 mmol/L) and magnesium to ≥2.0 mmol/L 3
If torsades persists despite magnesium, temporary pacing or isoproterenol infusion to increase heart rate is recommended 3.
Digoxin Toxicity with Ventricular Arrhythmias
IV magnesium is often administered when ventricular arrhythmias are present in digoxin toxicity 3. This is used as adjunctive therapy while the definitive treatment—digoxin-specific Fab antibodies—is being prepared for severe cases (digoxin >4 ng/mL with serious arrhythmias).
Magnesium Deficiency States
Hypomagnesemia Treatment
Mild deficiency 2:
- 1 g (8.12 mEq) IM every 6 hours for 4 doses
- Total: 32.5 mEq per 24 hours
Severe hypomagnesemia 2:
- Up to 250 mg/kg (approximately 2 mEq/kg) IM over 4 hours if necessary
- OR 5 g (40 mEq) added to 1 L D5W or normal saline, infused over 3 hours
- Critical point: Must not exceed renal excretory capacity
Total Parenteral Nutrition
Maintenance requirements 2:
- Adults: 8-24 mEq (1-3 g) daily
- Infants: 2-10 mEq (0.25-1.25 g) daily
Other Potential Uses (Lower Quality Evidence)
Acute Asthma Exacerbations
Recent 2025 meta-analysis shows IV MgSO4 as adjunct therapy significantly improves peak expiratory flow at 45 minutes (MD 18.50,95% CI 6.36-30.65) and reduces hospital admission rates (OR 0.45,95% CI 0.23-0.88) 4. However, this is not for routine use—reserve for severe cases refractory to first-line bronchodilators and corticosteroids 5.
Dosing for asthma 2:
- 3-4 g (30-40 mL of 10% solution) IV over 30 seconds with extreme caution
- Only if simpler measures have failed and no myocardial damage
Other Labeled Indications
The FDA label includes 2:
- Barium poisoning: 1-2 g IV to counteract muscle-stimulating effects
- Seizures (epilepsy, glomerulonephritis, hypothyroidism): 1 g IM or IV
- Paroxysmal atrial tachycardia: 3-4 g IV over 30 seconds (only if simpler measures failed, no myocardial damage)
- Cerebral edema reduction: 2.5 g IV
Administration and Safety Considerations
Rate of administration 2:
- Generally should not exceed 150 mg/minute (1.5 mL of 10% solution)
- Exception: severe eclampsia with active seizures
- Must dilute to ≤20% concentration for IV infusion
Drug incompatibilities 2:
- May precipitate with various solutions
- Reduces antibiotic activity of streptomycin, tetracycline, and tobramycin when given together
Toxicity signs 3:
- Areflexia progressing to respiratory depression at high serum concentrations
- Risk is very small with typical doses (1-2 g) for torsades de pointes
Common pitfall: The most frequent error is failing to monitor patellar reflexes, respiratory rate, and urine output during prolonged infusions in preeclampsia. Loss of reflexes is the earliest sign of toxicity and mandates immediate cessation.